Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb, IgG1, Human, Monoclonal

Catalog Number: ABI-12-9156-50
Article Name: Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb, IgG1, Human, Monoclonal
Biozol Catalog Number: ABI-12-9156-50
Supplier Catalog Number: 12-9156-50
Alternative Catalog Number: ABI-12-9156-50-50UG
Manufacturer: Abeomics
Host: Human
Category: Antikörper
Application: FACS
Species Reactivity: Human
Alternative Names: CTLA-8,CTLA8,IL-17,IL-17A,IL17
Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Clonality: Monoclonal
Isotype: IgG1
Purity: Purified from cell culture supernatant by affinity chromatography
Target: IL17A
Application Dilute: FACS 1:100